PNLIP and early-onset autosomal dominant Alzheimer disease: Furthermore, the phenolic compounds contained in the supplements possess inhibitory properties toward certain enzymes such as α-amylase, α-glucosidase, pancreatic lipase, cholinesterase, cyclooxygenases, and 5-lipohygenase, making them even more valuable products capable of being used to manage the following diseases: diabetes, obesity, Alzheimer’s disease, and skin hyperpigmentation [9,26].